Pharmacokinetics of the low molecular weight heparin Fragmin® D in dogs;Pharmakokinetik des niedermolekularen heparins Fragmin® D beim hund

Berliner und Munchener Tierarztliche Wochenschrift

Volumn 113, Issue 3, 2000, Pages 103-107

  Grebe, S ^b   Jacobs, C ^b   Kietzmann, M ^b   Mischke, R ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b NONE

Author keywords

Anti factor Xa activity; Dog; Low molecular weight heparin; Pharmacokinetics

Indexed keywords

DALTEPARIN;

ANIMAL; ARTICLE; BLOOD; DOG; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; DALTEPARIN; DOGS; HALF-LIFE; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS;

ANIMALIA; CANIS FAMILIARIS;

EID: 0034109327     PISSN: 00059366     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Andrassy, K., U. Eschenfelder (1996): Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb. Res. 81, Suppl. 2, 29-38.
2. Andriuoli, I., R. Mastacchi, M. Barbanti, M. Sarret (1985): Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats. Haemostasis 15, 324-330.
3. Bara, L., E. Billaud, G. Gramond, A. Kher, M. Samama (1985): Comparative pharmacokinetics of low molecular weight heparin (PK 10 169) and unfractioned heparin after intravenous and subcutaneous administration. Thromb. Res. 39, 631-636.
4. Bhargava, A. S., C. Schöbel, P. Günzel (1981): Characterization of a new potent heparin. Arzneim.-Forsch./Drug Res. 30, 79-82.
5. Barzu, T., P. Molho, G. Tobelem, M. Petitou, J. Caen. (1985): Binding and endocytosis of heparin by human endothelial cells in culture. Biochim. Biophys. Acta. 845, 196-203.
6. Barzu, T., J. L. Van Rijn, M. Petitou, G. Tobelem, J. P. Caen (1987): Heparin degradation in the endothelial cells. Thromb. Res. 47, 601-609.
7. Bergqvist, D., U. Hedner, E. Sjörn, E. Holmer (1983): Anticoagulant effects of two types of low molecular molecular weight heparin administered subcutaneously. Thromb. Res. 32, 381-391.
8. Bjornsson, T. D., K. M. Wolfram, B. B. Kitchell (1982): Heparin kinetics determined by three assay method. Clin. Pharmacol. Ther. 31, 104-113.
9. Boneu, B., C. Caranobe, A. M. Gabaig, D. Dupouy, P. Sie (1987): Evidence for a saturable mechanism of disappearance of standard heparin in rabbits. Thromb. Res. 46, 835-844.
10. Bratt, G., E. Törnebohm, D. Lockner, K. Bergström (1985): A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb. Haemost. 53, 208-211.
11. Bratt, G., E. Törnebohm, L. Wilund, D. Lockner (1986): Low molecular weight heparin (Kabi 2165, Fragmin): Pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb. Res. 42, 613-620.
12. Brindley, C. J., T. Taylor, V. Diness, P. B. Oestergaard, L. F. Chasseaud (1993): Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (logiparin), a low molecular weight heparin, in dogs. Xenobiotica 23, 575-588.
13. Cade, J. F., M. R. Buchanan, B. Boneu (1984): A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation. Thromb. Res. 35, 613-625.
14. Dawes, J., D. S. Pepper (1979): Catabolism of low-dose heparin in man. Thromb. Res. 14, 845-640.
15. DeSwart, C. A., B. Nijmeyer, J. M. Roelofs, J. J. Sixma (1982): Kinetics of intravenously administered heparin in normal humans. Blood 60, 1251-1258.
16. Fareed, J., W. Jeske, V. Eschenfelder, O. Iqbal, D. A. Hoppensteadt, A. Ashan (1996): Preclinical Studies on a low molecular weight heparin. Thromb. Res. 81, Suppl. 2, 1-27.
17. Friedmann, Y., C. Arsenis (1974): Studies on the heparin sulphamidase activity from rat spleen: Intracellular distribution and characterization of the enzyme. Biochem. J. 139, 699-708.
18. Gentry, P. A. (1977): Interaction of heparin with canine coagulation proteins: in vivo and in vitro studies. Can. J. Comp. Med. 41, 396-403.
19. Glimelius, B., C. Busch, M. Hook (1978): Binding of heparin on the surface of cultured human endothelial cells. Thromb. Res. 31, 773-782.
20. Grimaudo, V., A. Omri, E. K. Kruithof, J. Hauen, F. Bachmann (1988): Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination. Thromb. Haemost. 59, 388-391.
21. Harenberg, J. (1990): Pharmacology of low molecular weight heparins. Semin. Thromb. Hemost. 16, 12-19.
22. Harenberg, J., C. Giese, A. Knödler, Y. Ordu, R. Zimmermann (1985): Toxikologie und klinische Pharmakologie niedermolekularer Heparine. In: Schmitz-Hübner, U., J. van de Loo (Hrsg.): Niedermolekulares Heparin. Verlag Schattauer, Stuttgart-New York, S. 1-9.
23. Harenberg, J., G. Stehle, J. Augustin, R. Zimmermann (1989): Comparative human pharmacology of low molecular weight heparins. Semin. Thromb. Hemost. 15, 414-423.
24. Harenberg, J., G. Huhle, L. Piazolo, R. Malsch (1997): Niedermolekulare Heparine. Prophylaxe und Therapie thromboembolischer Erkrankungen. Hautarzt 48, 852-864.
25. Hirsh, J., M. N. Levine (1992): Low molecular weight heparin. Blood 79, 1-17.
26. Hirsh, J., T. E. Warkentin, R. Raschke, C. Granger, E. M. Ohman, J. E. Dalen (1998): Heparin and low molecular weight heparin: mechanismus of action, pharmaco-kinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114, Suppl. 5, 489-510.
27. Jacobs, Ch., S. Grebe, M. Kietzmann, R. Mischke (1999): Pharmakokinetik des unfraktionierten Heparins Liquemin beim Hund nach intravenöser und subkutaner Injektion basierend auf der Anti-Faktor-Xa-Aktivität. Dtsch. Tierärztl. Wochenschr. (im Druck).
28. Kandrotas, R. J. (1992): Heparin pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 22, 359-374.
29. Klein, W., A. Buchwald, W. E. Hillis, S. Monrad, G. Sanz, Turpie AG, J. Van der Meer, E. Olaisson, S. Undeland, K. Ludwig (1997): Comparison of low molecular weight heparin with unfractioned heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: The Fragmin in unstable coronary artery disease study (FRIC). Circulation 96, 61-68.
30. Lockner, D., G. Bratt, E. Tornebohm, W. Aberg (1986): Pharmacokinetics of intravenously and subcutaneously administered Fragmin in healthy volunteers. Haemostasis 16, Suppl. 2, 8-10.
31. Mammen, E.F. (1990): Why low molecular weight heparin? Semin. Thromb. Hemost. 16, 1-5.
32. Mahadoo, J., L. Hiebert, L. B. Jaques (1977): Vascular sequestration of heparin. Thromb. Res. 12, 773-782.
33. McAllister, B. M., D. J. Demis (1966): Heparin metabolism: isolation and characterization of uroheparin. Nature 212, 293-294.
34. Michels, M. (1996): Untersuchungen zum Pathomechanismus zur Labordiagnostik und zur Therapie der Heparin-assozierten Thrombozytopenie. Gießen, Univ., Fachber. Vet. Med., Diss.
35. Mombelli, G., J. Schaedelin, E. A. Beck (1977): Pharmakokinetik von Heparin nach einmaliger intravenöser und subkutaner Injektion. Schweiz. Med. Wochenschr. 107, 810-815.
36. Palm, M. (1990): Pharmacodynamic and pharmacokinetic properties of heparin and low molecular weight heparin fragments. Uppsala, Univ., Fachber. Klin. Chem., Diss.
37. Palm, M., C. Mattson (1987): Pharmacokinetics of heparin and a low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb. Haemost. 58, 932-935.
38. Samama, M. M., L. Bara, I. Gouin-Thibault (1996): New data on the pharmacology of heparin and low molecular weight heparins. Drugs 52, Suppl. 7, 14-15.
39. Uzan, A., J. Marin, J. Mardiguian, M. Trillou, T. Kioseff, C. Rougeot (1987): Etude pharmacocinétique comparée, chez le chien, d'une hèparin de bas poids moléculaire (Enoxaparine) et de l'héparine, par marquage au soufre 35. Ann. Pharm. Fr. 45, 429-437.